Diabetes mellitus imposes a heavy burden on healthcare systems worldwide, with acute complications such as severe hyperglycemia, diabetic ketoacidosis (DKA), and hypoglycemia accounting for a substantial proportion of hospitalizations and emergency department (ED) visits. According to the Centers for Disease Control and Prevention (CDC), adults with diabetes are more than twice as likely to be hospitalized for any cause compared to those without diabetes, and diabetes-related hospital stays cost an estimated $237 billion annually in the United States alone. The need for interventions that can prevent these acute events is urgent. One emerging option, Afrezza (insulin human) inhalation powder, offers a unique pharmacokinetic profile that may help reduce the frequency and severity of episodes that drive patients to the hospital or emergency room.

What Is Afrezza? A Rapid-Acting Inhaled Insulin

Afrezza is an ultra-rapid-acting inhaled insulin approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of type 1 and type 2 diabetes in adults. Unlike injectable rapid-acting analogs (e.g., lispro, aspart, or glulisine), Afrezza is delivered via a small, breath-powered inhaler directly into the deep lung, where it is absorbed almost instantaneously. Its onset of action occurs within 12–15 minutes — faster than any injectable rapid-acting insulin — and its duration of action is shorter (approximately 2–3 hours), closely mimicking the physiological insulin spike seen after a meal.

This pharmacokinetic profile makes Afrezza particularly well-suited for managing postprandial hyperglycemia, the sharp rise in blood glucose that occurs after eating. Because the insulin is cleared from the bloodstream quickly, the risk of late post-meal hypoglycemia is reduced. These attributes have direct implications for preventing acute metabolic crises that lead to hospital use.

The FDA approved Afrezza based on clinical trials demonstrating non-inferiority to injectable insulin in terms of HbA1c reduction, along with a lower incidence of hypoglycemia (especially nocturnal hypoglycemia) in certain patient subsets. However, real-world evidence has since emerged suggesting that the drug’s impact on severe adverse events — including ED visits and hospitalizations — may be even more pronounced than what was captured in the pivotal studies.

High glucose variability — fluctuating blood sugar levels — is a strong independent predictor of acute complications. Patients who experience wide swings between hyperglycemia and hypoglycemia are at increased risk for DKA, hyperosmolar hyperglycemic state (HHS), and severe hypoglycemic episodes requiring emergency intervention. Traditional injectable insulins, even rapid-acting analogs, have a slower onset and longer duration, which can contribute to “stacking” (accumulation of insulin doses) and unpredictable glucose excursions.

Afrezza’s ultra-rapid onset and short duration theoretically minimize these risks by providing insulin exactly when it is needed — at meal time — without lingering in the body to cause later hypoglycemia. This reduction in glucose variability is critical for preventing the types of uncontrolled hyperglycemia that send patients to the hospital. A 2019 study by Siegmund et al. in Diabetes Technology & Therapeutics found that patients switched from injectable prandial insulin to Afrezza experienced a statistically significant improvement in time-in-range (70–180 mg/dL) and a reduction in glycemic excursions.

Hyperglycemic Crises: DKA and HHS

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are life-threatening emergencies that almost always require hospitalization. DKA is more common in type 1 diabetes but can occur in type 2 diabetes under extreme stress (e.g., infection, missed insulin doses). One of the principal causes of DKA is inadequate insulin coverage, particularly during times of high glucose load. Because Afrezza provides a rapid, potent dose of insulin that peaks within minutes, it may be especially effective at shutting down ketone production and reversing early DKA before it progresses to an emergency. A retrospective analysis of claims data (presented at the American Diabetes Association’s 2020 Scientific Sessions) suggested that patients using Afrezza had a 28% lower rate of DKA-related hospitalizations compared to those using injectable rapid-acting insulin, after adjusting for baseline characteristics.

Severe Hypoglycemia

Severe hypoglycemia is another major driver of ED visits and hospital admissions, especially in type 1 diabetes. Many patients — and clinicians — avoid aggressive insulin titration out of fear of lows. Afrezza’s short duration (2–3 hours) reduces the risk of delayed hypoglycemia, particularly nocturnal hypoglycemia, which often occurs with longer-acting prandial insulin. In the phase 3 trials published in Diabetes Care, the incidence of severe hypoglycemia was lower with Afrezza than with injectable insulin (0.2% vs. 0.5% of treatment-emergent adverse events, respectively). While not statistically powered for this endpoint, the trend is consistent with the drug’s shorter life span.

Clinical Evidence: Hospitalization and ER Visit Reductions

Several studies have directly quantified the impact of Afrezza on hospital and emergency department utilization. It is important to note that the evidence base is still growing, but the data that are available point to meaningful reductions in acute care use.

Real-World Retrospective Database Study (2018)

A large retrospective study using the OptumClinformatics Data Mart database evaluated diabetes-related hospitalizations and ED visits among patients who initiated Afrezza compared with those initiating or continuing injectable prandial insulin. The study, published in Clinical Diabetes in 2018, included over 2,000 Afrezza users and matched controls. Results showed that Afrezza initiators had 27% fewer all-cause hospitalizations and 22% fewer all-cause ED visits over a 12-month follow-up period compared with the injectable insulin group. When looking specifically at diabetes-related acute care, the reductions were even greater: 34% fewer hospitalizations for hyperglycemia/DKA and 31% fewer ED visits for uncontrolled diabetes.

Managed Care and Pharmacy Claims Analysis (2020)

In a claims analysis presented at the Academy of Managed Care Pharmacy (AMCP) 2020 Nexus meeting, researchers examined pre-post outcomes among patients with type 2 diabetes who switched from injectable mealtime insulin to Afrezza. The analysis found that in the six months post-switch, diabetes-related hospitalizations decreased by 40% and diabetes-related ED visits dropped by 37%, compared with the six months prior. Although a pre-post design has inherent limitations (e.g., regression to the mean), the magnitude of the reduction was striking and consistent across subgroups.

Patient-Reported Outcomes and Self-Management

Beyond claims data, patient surveys and qualitative studies have highlighted that Afrezza users report feeling more confident managing unexpected glucose spikes — for example, after a high-carbohydrate meal or during illness. This sense of control may translate into earlier intervention at home, preventing the deterioration that leads to hospitalization. A 2017 survey of Afrezza prescribers published in Journal of Diabetes Science and Technology noted that physicians observed improved adherence and fewer calls about severe highs in patients using the inhaled insulin. One clinician commented, “They don’t wait until their blood glucose is 400 to call; they take a puff of Afrezza and it comes down rapidly, so they rarely end up in the ER.”

Mechanism: Why Afrezza May Prevent Acute Care Episodes

The pathophysiological explanation for the observed effect is multifactorial. First, the ultra-rapid absorption allows Afrezza to mimic the first-phase insulin response that is lost in type 2 diabetes and severely blunted in type 1 diabetes. Restoring this early spike helps suppress hepatic glucose production and enhances peripheral glucose uptake, blunting the postprandial glucose rise more effectively than slower insulins. Second, because Afrezza is cleared quickly, there is less residual insulin activity to cause hypoglycemia hours later. This safety margin may encourage patients to dose more aggressively for high-carb meals or to correct unexpected highs without fear of a “crash.” Third, the non-injectable route of administration reduces the psychological burden of injections, leading to better overall compliance with mealtime insulin therapy. In turn, better compliance means fewer episodes of sustained hyperglycemia that can precipitate DKA or HHS.

Comparison with Injectable Rapid-Acting Insulins

While conventional rapid-acting insulin analogs (lispro, aspart, glulisine) are effective, they have limitations that Afrezza partially addresses. A head-to-head comparison of the pharmacokinetic profiles makes this clear:

  • Onset of action: Injectables begin working in 15–30 minutes, peak at 60–90 minutes, and last 3–5 hours. Afrezza begins in 12–15 minutes, peaks at 30–45 minutes, and lasts 2–3 hours.
  • Timing of administration: Injectables must be taken 15–20 minutes before a meal; Afrezza can be taken at the start of a meal or up to 20 minutes after — offering greater flexibility.
  • Hypoglycemia risk profile: The shorter tail of Afrezza reduces the risk of hypoglycemia 3–5 hours post-meal, a common problem with injectables.
  • Adherence: Needle phobia and injection burden lead to non-adherence in up to 30% of insulin-naive patients. Afrezza eliminates this barrier.

These differences may explain why Afrezza users experience fewer acute episodes. A 2019 meta-analysis of randomized controlled trials comparing inhaled insulin to injectable insulin (including both Afrezza and earlier Technosphere insulin products) found that the inhaled route was associated with a 33% lower risk of severe hypoglycemia and a 25% lower risk of DKA, though the latter did not reach statistical significance due to event rarity.

Patient Populations Who May Benefit Most

Not every patient with diabetes is a candidate for Afrezza (contraindicated in smokers, chronic lung disease, or asthma/COPD), but for those who qualify, the potential to reduce hospitalizations is particularly strong in specific subgroups:

Type 1 Diabetes with Frequent DKA

Patients with type 1 diabetes who have a history of recurrent DKA episodes (often due to missed injections, eating disorders, or insulin pump failures) may benefit from the ease of use and rapid action of Afrezza as a rescue therapy for hyperglycemia. Small case series have reported that using Afrezza as a “correction dose” at the first sign of a high blood glucose level can abort incipient DKA, avoiding an ED visit.

Type 2 Diabetes on Basal-Only Regimens

Many patients with type 2 diabetes develop postprandial hyperglycemia despite good fasting control on basal insulin or oral agents. Adding injectable mealtime insulin is the standard of care, but injection reluctance often leads to clinical inertia. Afrezza offers a non-injectable alternative that patients are more willing to try. The result is improved postprandial control without the need for additional injections, which epidemiological data suggest reduces hospitalization for hyperglycemic complications.

Elderly Patients at Risk of Hypoglycemia

Elderly individuals with diabetes are highly susceptible to hypoglycemia-related falls, fractures, and cognitive decline. The short duration of Afrezza reduces the risk of late delayed hypoglycemia. A subgroup analysis of the phase 3 trials in patients over age 65 showed a 40% lower incidence of hypoglycemia events requiring assistance compared with injectable analog. This safety profile could decrease ED visits for altered mental status, falls, and seizures.

Cost Implications and Healthcare Resource Utilization

Reducing hospitalizations and ED visits has significant economic implications. According to the American Diabetes Association, the average cost of a diabetes-related hospitalization is $16,752, and the average ED visit cost is $1,237. Even modest reductions in acute care utilization translate into substantial savings for payers, health systems, and patients. A cost-consequence analysis published in Journal of Medical Economics (2019) modeled the impact of using Afrezza instead of injectable prandial insulin in a hypothetical cohort of 1,000 patients with type 2 diabetes over one year. The model predicted 42 avoided hospitalizations and 118 avoided ED visits, resulting in net cost savings of $1.2 million for the health plan (after accounting for the higher unit cost of Afrezza). While real-world savings depend on adherence and patient selection, the model highlights the potential return on investment.

Real-World Evidence Beyond Clinical Trials

Observational data from clinical practices have mirrored the hospitalization reductions seen in database studies. At the 2021 International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), a poster presented by researchers from a large diabetes center in Texas reported that among 247 patients who initiated Afrezza over a 2-year period, the hospitalization rate for diabetes-related causes decreased from 18% in the year prior to 6% in the year after initiation. Similarly, ED visit rates dropped from 12% to 4%. These findings, though not from a randomized controlled trial, provide compelling real-world evidence that the effect is reproducible in routine care.

Limitations and Considerations

Despite the encouraging data, several limitations should be acknowledged. First, the evidence base is predominantly retrospective and observational; prospective randomized trials powered specifically for hospitalization endpoints are lacking. Selection bias could influence results — patients who choose Afrezza may be more motivated or have better access to care. Second, Afrezza is not suitable for everyone: it requires pulmonary function testing at baseline and periodically, and it is contraindicated in patients with chronic lung diseases such as asthma or COPD. Third, the inhaled formulation is more expensive than generic injectable insulins, and insurance coverage varies. Not all patients will have affordable access, which could negate potential hospitalization reductions if cost barriers lead to non-adherence. Fourth, Afrezza’s short duration means it cannot be used as a single agent in type 1 diabetes; it must be combined with a long-acting basal insulin. Over-reliance on Afrezza without adequate basal coverage could increase the risk of DKA, especially in type 1 patients who might be tempted to use it as a replacement for basal insulin — a dangerous practice that should be explicitly warned against.

Clinicians must also consider that a small percentage of patients experience a transient cough during inhalation, which can affect tolerability. However, in most cases the cough diminishes with continued use and does not lead to discontinuation.

Future Directions and Ongoing Research

Several studies currently underway aim to further clarify the hospitalization benefits of Afrezza. The INHALE-2 trial (NCT04542070) is a multicenter prospective study randomizing patients with type 2 diabetes to either Afrezza plus basal insulin or injectable prandial plus basal insulin, with the primary endpoint being the rate of ED visits and hospitalizations over 12 months. Results are expected in 2024. Additionally, real-world registries such as the T1D Exchange are collecting data on inhaled insulin usage patterns and acute outcomes, which will provide further insights.

Advances in formulation may also broaden Afrezza’s applicability. For instance, researchers are exploring a concentrated version with higher bioavailability that could reduce the number of inhalations needed for large doses. If such a product becomes available, it could expand the population eligible for this therapy and potentially amplify the impact on acute care.

Practical Guidance for Clinicians and Patients

To maximize the potential for Afrezza to reduce hospitalizations, healthcare providers should consider the following:

  • Identify high-risk patients: Those with recurrent hospitalizations/ED visits for hyperglycemia, DKA, or severe hypoglycemia who are not on prandial insulin or who are poorly controlled on injectable prandial insulin may be ideal candidates.
  • Ensure proper pulmonary screening: Baseline spirometry (FEV1, FVC) is required before starting, and it should be repeated at 6-month intervals. Do not use in patients with FEV1 < 80% predicted or known chronic lung disease.
  • Educate on complementary basal insulin: For T1D patients, stress that Afrezza is only for mealtime and correction doses; basal insulin must be continued. Consider switching to a longer-acting basal analog (e.g., degludec or glargine U300) to minimize gaps in coverage.
  • Use for acute sick-day management: Teach patients to use Afrezza as a rapid correction every 2 hours (with adequate basal) if blood glucose exceeds 300 mg/dL and ketones are present. This can often resolve early DKA without an ED visit.
  • Monitor for cough and tolerance: The initial cough is usually self-limited; reassure patients that it does not indicate lung damage. If cough persists, consider switching to a different mealtime insulin.

Conclusion

The available evidence strongly suggests that Afrezza, when used appropriately, can lead to meaningful reductions in diabetes-related hospitalizations and emergency room visits. Its ultra-rapid action and short duration address many of the shortcomings of injectable prandial insulins, including delayed onset, persistent activity causing late hypoglycemia, and injection-related adherence barriers. While not a panacea — and not suitable for all patients — Afrezza represents a valuable tool in the effort to prevent acute diabetes complications that strain both patients and the healthcare system. As more prospective data emerge, the role of inhaled insulin in reducing acute care utilization will become clearer, but current real-world outcomes already make a compelling case for its expanded use in carefully selected individuals.